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T
he basis for the clustering of obesity with insulin
resistance, type 2 diabetes, and related patholo-
gies of the metabolic syndrome is complex but
involves altered metabolic function and sub-
strate ﬂow both within and between insulin-responsive fat,
muscle, and liver tissues (1,2). Since the discovery of
leptin in the 1990s, the focus on the normal endocrine and
(more recently) the pathological inﬂammatory roles of
adipose tissue has been rewarded with ever-accelerating
advancements in our understanding of metabolic disease.
However, it is worth noting that endocrine/inﬂammatory
dysfunction of adipose tissue does not naturally occur
independently of insulin resistance within adipocytes
themselves. Rather, both naturally emerge from the his-
tory of the expanding adipose compartment in obesity
(2,3). While a complete description of adipose tissue
expansion is lacking, an increase in size of existing adipo-
cytes (hypertrophy) appears to predominate in early
stages, followed only later by the appearance of smaller,
apparently newer adipocytes (hyperplasia) (4).
A key element in diagnosis of the metabolic syndrome,
as well as an important diabetes risk factor, is expanded
central, or visceral, adiposity. For example, stepwise and
multiple regression models involving MRI-determined
masses of all adipose depots— controlled for age, obesity,
and serum triglyceride and nonesteriﬁed fatty acid lev-
els—identify visceral fat as a signiﬁcant risk factor for
insulin resistance (5). Moreover, human visceral adipo-
cytes examined ex vivo have been known for some time to
be insulin resistant relative to subcutaneous adipocytes.
(For one example, see ref. 6). The basis for this resistance
is complex but likely involves increased exposure to
cortisol, adrenergic stimulation, and, perhaps, developing
hyperinsulinemia.
In the absence of postprandial insulin, adrenergic stim-
ulation causes cyclic AMP (cAMP)-dependent phosphory-
lation of both perilipin, which coats the adipocyte lipid
droplet, and hormone-sensitive lipase, allowing hydrolytic
release of fatty acids from triglyceride for their use as fuel
elsewhere (7). Insulin exerts antilipolytic activity by acti-
vating PDE3B, a cAMP phosphodiesterase, as well as
promoting reesteriﬁcation of fatty acids to newly gener-
ated glycerol 3-phosphate. Thus, the visceral focus of
adipose insulin resistance contributes strongly to another
feature of the metabolic syndrome, nonalcoholic fatty liver
disease, via increased return of hydrolyzed fatty acid to
the portal circulation (8). Increased lypolysis owing to
adipocyte insulin resistance may also contribute to muscle
insulin resistance and impairment of -cell secretory func-
tion via lipotoxicity (2,3).
A somewhat recently appreciated feature of the expand-
ing adipose compartment of obesity is the occurrence of
localized hypoxia (reviewed in ref. 9). The presence of
hypoxic regions within adipose tissues of obese rodents
has been demonstrated by anaerobic adductive chemistry
in vivo, increased local lactate concentrations, and speciﬁc
hypoperfusion of adipose tissue (10). The presence of
hypoxia in human adipose tissue is at least strongly
implied, given the similar hypoperfusion that is character-
istic of human obesity (9).
The principle sensor and mediator of the adipocyte
response to hypoxia is hypoxia-inducible factor (HIF)-1, a
heterodimeric (/) transcription factor, of which the
-subunit (HIF-1 or HIF-2) is directly regulated by
oxygen tension. HIF-1 protein is expressed at higher
levels in adipose tissue of obese rodents, and its mRNA
has been reported to be upregulated in fat and inﬁltrating
macrophages of obese humans (9). Under normoxic con-
ditions, HIF-1 undergoes prolyl hydroxylation and is de-
graded by the ubuiquitin/proteasomal route; by contrast, in
hypoxia, its hydroxylation is disfavored, allowing newly
synthesized HIF-1 to accumulate, complex with its -sub-
unit, and activate gene transcription. At some promoters, at
least, this takes place in cooperation with cAMP-responsive
element–binding protein (CREB) and its coactivator p300.
In general, the transcription of HIF-1 target genes serves
to alter the local microenvironment by promoting angio-
genesis (vascular endothelial growth factor), tissue re-
modeling (matrix metalloproteinases), and inﬂammation
(interleukin-6, plasminogen activator inhibitor-1, and, per-
haps, tumor necrosis factor-). As with HIF-1 itself,
genes in the last category may also be upregulated in
nearby macrophages, which cluster about dying adipo-
cytes; this suggests a potentiation of localized inﬂamma-
tion by the hypoxic microenvironment (2,10). Another
class of HIF-1 target genes likely promotes adipocyte
survival via adaptation to anaerobic metabolism. Among
these are pyruvate dehydrogenase kinase—which shunts
acetyl-CoA away from mitochondrial oxidation via conver-
sion into lactate—and GLUT1, which promotes insulin-
independent uptake of glucose. Importantly, production of
the insulin-sensitizing adipokine adiponectin/Acrp30 is
also decreased during hypoxia, paralleling the decrease in
serum adiponectin levels in human obesity. Thus, activa-
tion of the HIF-1 program seems likely to worsen inﬂam-
mation, impair healthy adipose endocrine function, and
contribute to whole-body insulin resistance.
Surprisingly, a relationship between hypoxia and insulin
resistance within adipocytes per se has not, until now,
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al. (11) close this loop by demonstrating that in murine
preadipocyte cell lines and human subcutaneous abdomi-
nal adipocytes, examined in vitro, hypoxia leads to insulin
resistance. This appears to occur solely through inhibition
of insulin receptor phosphorylation. While the universality
of this ﬁnding—say in muscle under exercise—remains to
be determined, it is somewhat satisfying, intellectually,
given the important oppositional roles of cAMP/CREB-
and insulin-mediated signaling in adipocyte metabolism.
Though the exact mechanism by which insulin receptor
autophosphorylation is inhibited remains unclear, it does
depend upon the activity of HIF-1. A curious aspect of this
dependence is its rapid reversibility; insulin receptor phos-
phorylation was restored after a quite brief return of
adipocytes (45 min) to normoxic conditions. Thus, it is at
least formally possible that the inhibition of insulin recep-
tor phosphorylation might depend on HIF-1 itself. More
probably, some activity of unknown downstream targets
of HIF-1 causes the inhibition of insulin receptor phos-
phorylation, and this activity is rapidly downregulated by
the return to normoxic conditions.
But what is the net contribution of this insulin resis-
tance to disease progression? As expected, the hypoxia-
induced insulin resistance reported by Regazetti et al. was
accompanied by increased lipolysis (monitored through
glycerol production). The released fatty acids might be
expected to further perturb the local tissue environment,
or—if they actually enter the circulation—promote sys-
temic insulin resistance. However, it is unclear whether
hypoxia is likely to be more (or less) prevalent in visceral
adipose tissue important to disease than it is elsewhere.
Further, a known feature of insulin resistance in human
visceral adipose tissue is the presence of postreceptor
signaling defects, including—but perhaps not limited to—
the downregulation of IRS-1 (6). This was not observed by
Regazzetti et al. At this point, an examination of rodents
with, for example, decreased HIF-1 function might be
informative concerning whether the HIF-1 program in
hypoxic adipose tissue, including the associated insulin
resistance, is purely pathological or is instead an adaptive
process.
This could depend on whether the hypoxia is intermit-
tent or chronic. Because of its rapid reversibility, it is
certainly tempting to view HIF-1–mediated insulin resis-
tance as part of a dynamic solution to the problem of how
to best “pack” hydrophobic triglyceride into hypertophic
adipocytes while maintaining perfusion. To put it most
simply, increased lipolysis would slow hypertrophy while
the HIF-1 program would modify the local environment to
promote perfusion and genesis of the new, smaller adipo-
cytes typical of later obesity (4,9). Indeed, well-deﬁned
(CD34
CD31
) adipocyte progenitor cells—isolated from
the stromal vascular fraction of adipose tissue of obese
adults—display elevated HIF-1 expression that is posi-
tively correlated with BMI (4). Moreover, exposure of
these progenitors to hypoxia and its related cytokine
proﬁle (e.g., interleukin-6) promotes differentiation into
adipocytes. Given the therapeutic value of even moderate
weight loss in the early stages of diabetes, it thus appears
that hypoxia-induced insulin resistance may be just one
feature of a normally adaptive remodeling process that
becomes pathological only in the continued presence of
hypernutrition or other external stimulus.
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